Risperidone Long-acting Injectable (LAI) for Bipolarity
This study is completed in China, in Colombia, in Germany, .... It is testing Risperidone Long-acting Injectable (LAI) for Bipolarity.
BipolarityDrugFrom 18 Years to 65 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether Risperidone may be useful for adults experiencing bipolarity.
What would participation involve?
Participants may receive Risperidone, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in China, in Colombia, and in Germany.
Who is it mainly for?
This study appears to be mainly for adults with bipolarity.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateNovember 2006
Recruitment status
Completed
Enrollment listed in the registry
585
Sponsor
Janssen Pharmaceutica N.V., Belgium
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
China, Colombia, Germany, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT00391222
Official title
A Randomized, Double Blind, Placebo and Active Controlled Parallel Group Study to Evaluate the Efficacy and Safety of Risperidone Long-acting Injectable (LAI) for the Prevention of Mood Episodes in the Treatment of Subjects With Bipolar I Disorder
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
China · 7 sites
Baoding
Baoding
Site status: Not listed — confirm with the team
Beijing
Beijing
Site status: Not listed — confirm with the team
Guangzhou
Guangzhou
Site status: Not listed — confirm with the team
Nanjing
Nanjing
Site status: Not listed — confirm with the team
Shanghai
Shanghai
Site status: Not listed — confirm with the team
Suozhou
Suozhou
Site status: Not listed — confirm with the team
Wuhan
Wuhan
Site status: Not listed — confirm with the team
Colombia · 6 sites
Barranquilla Atlantico
Barranquilla Atlantico
Site status: Not listed — confirm with the team
Bello Antioquia
Bello Antioquia
Site status: Not listed — confirm with the team
Bogotá
Bogotá
Site status: Not listed — confirm with the team
Bogotá S/N
Bogotá S/N
Site status: Not listed — confirm with the team
Medellin Antioquia
Medellin Antioquia
Site status: Not listed — confirm with the team
Pereira Risaralda
Pereira Risaralda
Site status: Not listed — confirm with the team
Germany · 3 sites
Freiburg im Breisgau
Freiburg im Breisgau
Site status: Not listed — confirm with the team
Hildesheim
Hildesheim
Site status: Not listed — confirm with the team
Oranienburg
Oranienburg
Site status: Not listed — confirm with the team
Greece · 1 site
Athens
Athens
Site status: Not listed — confirm with the team
India · 10 sites
Ahmedabad
Ahmedabad
Site status: Not listed — confirm with the team
Bangalore
Bangalore
Site status: Not listed — confirm with the team
Chennai
Chennai
Site status: Not listed — confirm with the team
Hyderabad
Hyderabad
Site status: Not listed — confirm with the team
Ludhiana
Ludhiana
Site status: Not listed — confirm with the team
Mangalore
Mangalore
Site status: Not listed — confirm with the team
Mumbai
Mumbai
Site status: Not listed — confirm with the team
New Delhi
New Delhi
Site status: Not listed — confirm with the team
Pune
Pune
Site status: Not listed — confirm with the team
Varanasi
Varanasi
Site status: Not listed — confirm with the team
Indonesia · 1 site
Jakarta
Jakarta
Site status: Not listed — confirm with the team
Jordan · 1 site
Amman
Amman
Site status: Not listed — confirm with the team
Lebanon · 1 site
Beirut
Beirut
Site status: Not listed — confirm with the team
Malaysia · 2 sites
Johor Bahru
Johor Bahru
Site status: Not listed — confirm with the team
Kuala Lumpur
Kuala Lumpur
Site status: Not listed — confirm with the team
Mexico · 7 sites
Mexico City
Mexico City
Site status: Not listed — confirm with the team
Mérida
Mérida
Site status: Not listed — confirm with the team
Monterrey
Monterrey
Site status: Not listed — confirm with the team
Puebla City
Puebla City
Site status: Not listed — confirm with the team
Tabasco
Tabasco
Site status: Not listed — confirm with the team
Tampico
Tampico
Site status: Not listed — confirm with the team
Zapopan
Zapopan
Site status: Not listed — confirm with the team
Peru · 2 sites
Lima
Lima
Site status: Not listed — confirm with the team
Lima Lima
Lima Lima
Site status: Not listed — confirm with the team
Philippines · 3 sites
Iloilo City
Iloilo City
Site status: Not listed — confirm with the team
Mandaluyong
Mandaluyong
Site status: Not listed — confirm with the team
Mandaue City
Mandaue City
Site status: Not listed — confirm with the team
Russia · 13 sites
Arkhangelsky District
Arkhangelsky District
Site status: Not listed — confirm with the team
Chelyabinsk
Chelyabinsk
Site status: Not listed — confirm with the team
Izhevsk
Izhevsk
Site status: Not listed — confirm with the team
Kazan’
Kazan’
Site status: Not listed — confirm with the team
Moscow
Moscow
Site status: Not listed — confirm with the team
Moscow Region
Moscow Region
Site status: Not listed — confirm with the team
Nizny Novgorod
Nizny Novgorod
Site status: Not listed — confirm with the team
Orenburg
Orenburg
Site status: Not listed — confirm with the team
Saint Petersburg
Saint Petersburg
Site status: Not listed — confirm with the team
Saratov
Saratov
Site status: Not listed — confirm with the team
Stavropol Na
Stavropol Na
Site status: Not listed — confirm with the team
Tomsk Na
Tomsk Na
Site status: Not listed — confirm with the team
Voronezh
Voronezh
Site status: Not listed — confirm with the team
South Africa · 4 sites
Bloemfontein
Bloemfontein
Site status: Not listed — confirm with the team
Cape Town
Cape Town
Site status: Not listed — confirm with the team
Durban
Durban
Site status: Not listed — confirm with the team
Pretoria
Pretoria
Site status: Not listed — confirm with the team
Taiwan · 2 sites
Tainan
Tainan
Site status: Not listed — confirm with the team
Taipei
Taipei
Site status: Not listed — confirm with the team
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT00391222. We help you review the study, but cannot decide medical eligibility.
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with bipolarity. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving Olanzapine, Placebo, Risperidone Long Acting Injectable (LAI). Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.
Who might this study be for?
This study may concern people with bipolarity; age range: From 18 Years to 65 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Janssen Pharmaceutica N.V., Belgium, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.